cannabinoid

Consumer cannabidiol company cbdMD Inc (NYSE: YCBD) announced Tuesday a new partnership with retired NFL players Steve Smith, Sr. and Jonathan Stewart. What Happened Smith and Stewart played together with the Carolina Panthers and are now reunited through a new partnership with cbdMD, best known...

The Food and Drug Administration issued an open "warning letter" Monday to Curaleaf Holdings Inc (OTC: CURLF) stating the vertically integrated cannabis operator is making illegal or false claims on its website and social media accounts. What Happened The FDA said it has determined...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a company that focuses on treating rare and near-rare neuropsychiatric disorders through cannabinoid therapies, said Tuesday it received a new U.S. patent for one of its cannabis-focused treatments. Zynerba said the U.S. Patent and Trademark Office...

Cannabis-flavored coffee and tea will become a reality in certain states in the United States and a Starbucks Corporation (NASDAQ: SBUX) "triple venti cannabis -- whatever" sounds more appealing than what any of its competitors would offer, CNBC's Jim Cramer said Friday. Triple Venti...

As Canada prepared for full legalization of weed and the cannabis industry in the United States was booming, more businesses joined the industry either as startups or as established companies that changed or diversified their business models. For publicly traded companies, announcing entry into...

For investors who are seeking exposure to the cannabis industry but consider pure-play companies too risky, there are many other interesting investment opportunities. Pharma and biotech companies have started to work with cannabis and its derivatives both natural and synthetic. In many cases,...

The global cannabis industry took two big steps forward this week. On Oct. 31, Mexico’s Supreme Court said the laws that ban recreational weed are unconstitutional, essentially opening the door for a potential legalization of pot in the future. The second major development took place across...

It’s been an eventful few weeks in the cannabis market. Then again, is it ever not eventful in cannabis? Between Tilray Inc (NASDAQ: TLRY) IPOing to become the first cannabis-producing company on a major American exchange, Aurora Cannabis’ (OTC: ACBFF) $2.5 billion acquisition of...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced Thursday its Phase 2 trial for ZYN002 in Fragile X syndrome found sustained improvements in patients’ core behavioral symptoms. The drug was well tolerated with no serious adverse events. Why It’s Important The candidate is the most...

Shares of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), a specialty pharmaceutical company that focuses on developing and commercializing pharmaceutically produced transdermal cannabinoid treatments, traded higher during Monday's pre-market session but then sold off after the opening bell. The...

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), which specializes in transdermal synthetic cannabinoid treatments, has a 25-percent probability for success in its treatment of adult epilepsy, an analyst said Tuesday. Cantor Fitzgerald analyst Elemer Piros said there were no surprises in the Q2 results...

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) to $208/ADS from $182/ADS after additional positive Epidiolex results. Epidiolex Significance The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and...

Cannabinoid drug developer GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) is ending an eventful 2016 on a high note. Shares were surging higher by 6.6 percent on Monday following new drug data out over the weekend and a strong fiscal Q4 earnings report out Monday. Over the weekend, the company reported...

The surprise election of Donald Trump has gotten most of the election-related headlines following Tuesday’s vote. However, Tuesday was also a landmark day for the marijuana legalization movement. Marijuana scored medical and/or recreational victories in eight of the nine states that voted on...

H.C. Wainwright & Co. believes that the current valuation of Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has not taken into consideration the potential increased success rate of ZYN002 for epilepsy. Therefore, the firm believes the stock has the potential to deliver more than 60 percent upside...